注册以创建品种、
财经事件和所关注作者内容的提醒
免费注册 已有账户? 登录
Adaptimmune Therapeutics PLC是一家临床阶段的生物制药公司。该公司专注于为癌症患者提供细胞疗法。它为实体瘤开发 T 细胞疗法,并报告了七种实体瘤适应症的临床反应(根据 RECIST 1.1)。它的平台能够识别癌症靶点,发现和开发对这些靶点有活性的细胞治疗候选物,并产生用于患者的治疗候选物。其候选细胞疗法包括使用基因工程T细胞受体的特异性肽增强亲和力受体(SPEAR)T细胞;肿瘤浸润淋巴细胞(TiL),其中患者自身的T细胞与其下一代技术共同给药,以及HLA非依赖性TCR(HiT),其中表面蛋白的靶向独立于肽-HLA复合物。其临床试验包括使用afamitres基因autoleucel的Spearhead-1 II期试验;通过ADP-A2M4CD8等的I期试验。
名称 | 年龄 | 任期 | 标题 |
---|---|---|---|
Lawrence M. Alleva | 71 | 2015 | Independent Non-Executive Director |
Adrian G. Rawcliffe | 49 | 2015 | CEO, Principal Accounting Officer & Director |
David M. Mott | 56 | 2015 | Independent Chairman of the Board of Directors |
Wolf H. Fridman | - | - | Member of the Scientific Advisory Board |
Ali Behbahani | 47 | 2015 | Independent Non-Executive Director |
Andy Sewell | - | - | Member of the Scientific Advisory Board |
Stephan A. Grupp | - | - | Member of the Scientific Advisory Board |
Mario Sznol | - | - | Member of the Scientific Advisory Board |
Kristen M. Hege | 60 | 2023 | Independent Non-Executive Director |
Wolf Herve Fridman | - | - | Member of the Scientific Advisory Board |
Thomas Gajewski | - | - | Member of the Scientific Advisory Board |
Michael Dustin | - | - | Member of the Scientific Advisory Board |
Malcolm K. Brenner | 71 | - | Member of the Scientific Advisory Board |
Priti Hegde | 52 | 2023 | Independent Non-Executive Director |
Garry E. Menzel | 60 | 2023 | Independent Non-Executive Director |
Andrew R. Allen | 58 | 2023 | Independent Non-Executive Director |
确定屏蔽%USER_NAME%?
如果屏蔽,您和%USER_NAME%都无法看到相互在Investing.com上发布的信息。
%USER_NAME%已成功添加至屏蔽列表
由于您刚刚取消屏蔽此人,因此必须等待48小时才能重新屏蔽。
您举报该评论的原因为:
谢谢您!
您的举报将会被发送到管理员进行审核